Biotech-Konzern: Drei deutsche Biontech-Standorte werden geschlossen
Für die Werke in Idar-Oberstein, Marburg und Tübingen hat sich kein Käufer gefunden. Biontech kündigt an, die Schließungen sozialverträglich zu gestalten.
The biotech conglomerate Biontech has announced that three of its German sites - located in Idar-Oberstein, Marburg, and Tübingen - will be closing in the coming years. This decision affects approximately 1,800 employees. Tübingen is slated to close at the end of 2027, Marburg at the beginning of 2028, and Idar-Oberstein at the end of 2028.
Biontech attributes the inability to sell the companies primarily to the challenging current market and investment climate. To make the closures more socially acceptable, the company claims it has agreed to additional severance conditions with the company council at each location. The Idar-Oberstein plant, with a rich history, produced Covid-19 mRNA vaccines and plasmid DNA, an essential raw material for mRNA vaccines and cell therapies.
Originally acquired from Swiss pharmaceutical company Novartis, Biontech invested millions in the site. Marburg's facility housed mRNA vaccines and plasmid DNA, as well as Curevac, a former competitor in the race to develop a coronavirus vaccine.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
